Guest Editor(s)
-
- Dr. Michael Lahn
iOnctura SA, Geneva, Switzerland.
Website | E-mail
-
- Dr. Jordi Rodon
- Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Website | E-mail
-
- Prof. Hendrik Tobias Arkenau
Drug Development Unit, Sarah Cannon Research Institute, London, UK.
Website | E-mail
Special Issue Introduction
Despite the clinical benefit obtained with current cancer immunotherapy, there is a large group of patients who do not respond or respond poorly to current therapies. In fact, some even show hyperprogression once immunotherapy is started. Underlying mechanisms of resistance are thought to be driving this lack of response to immunotherapy.
In the present special issue, the various concepts of resistance mechanisms will be summarized. This will include mechanisms of primary resistance, various barriers to immunotherapies, the selection of tumour clones that lead to resistance and finally the molecular changes within tumour cells rendering them resistant to therapy.
An important pillar for studying resistance is the available tools to detect and monitor resistance in patients. Biomarker tests that can assess emerging or pre-existing intrinsic or extrinsic factors leading to resistance are perhaps more than ever needed to direct physicians towards seeking novel therapies.
This special issue aims to compile a collection of updated research, review and expert opinion articles on resistance mechanisms, the available strategies to detect such developments and propose potential novel therapeutic approaches.
Sub-topics:
Concept of resistance to immunotherapy
Potential mechanisms of resistance to immunotherapy
Targets for overcoming resistance to immunotherapy
Keywords
Immunotherapy resistance, potential mechanisms of immunotherapy resistance, targets for overcoming immunotherapy resistance, immune checkpoints inhibitors
Submission Deadline
30 Apr 2023
Cancer Drug Resistance
